Literature DB >> 25318630

Transporting neonates with hypoxic-ischemic encephalopathy utilizing active hypothermia.

M D Weiss1, A Tang2, L Young3, L Irwin2, C Brophy2, V Larsen2, J Howard2, C Miller4, M Douglas-Escobar4.   

Abstract

OBJECTIVE: The objective of this report was to evaluate a servo-controlled active hypothermia device used during the transport of neonates with HIE. STUDY
DESIGN: Retrospective review of all cases of therapeutic hypothermia, both passive and active, using a servo-controlled device in a single regional referral neonatal intensive care unit from 2009-2013
RESULTS: An ambulance (43%), fixed wing aircraft (25%), or helicopter (32%) transported 28 neonates with active hypothermia. The servo-controlled device captured core temperatures in all 28 neonates, resulting in 2,985 minutes of data. All neonates attained a core temperature between 33-34 °C by 33 minutes of the transport. Once the neonates attained a core temperature, the average temperature for the remainder of the transport was 33 ± 0.2 °C. The neonates maintained the core temperature regardless of the type of transport vehicle.
CONCLUSION: Servo-controlled hypothermia enables rapid attainment of targeted temperatures and maintains the temperature throughout the transport process in both ground and air transport.

Entities:  

Keywords:  Active hypothermia; encephalopathy; hypoxic-ischemic; neonates; transport

Mesh:

Year:  2014        PMID: 25318630     DOI: 10.3233/NPM-14814018

Source DB:  PubMed          Journal:  J Neonatal Perinatal Med        ISSN: 1878-4429


  2 in total

1.  Provision of Therapeutic Hypothermia in Neonatal Transport: A Longitudinal Study and Review of Literature.

Authors:  Alok Sharma
Journal:  Cureus       Date:  2015-05-26

2.  Passive hypothermia (≥35 - <36°C) during transport of newborns with hypoxic-ischaemic encephalopathy.

Authors:  Aurélie Sellam; Noëlla Lode; Azzedine Ayachi; Gilles Jourdain; Stéphane Dauger; Peter Jones
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.